Akt SUM Oylation regulates cell proliferation and tumorigenesis

Cancer Research

Volumn 73, Issue 18, 2013, Pages 5742-5753

  Li, Rong ^a   Wei, Jie ^a   Jiang, Cong ^a   Liu, Dongmei ^a   Deng, Lu ^a   Zhang, Kai ^a   Wang, Ping ^a  

^a EAST CHINA NORMAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ARGININE; GLUTAMIC ACID; LYSINE; PROTEIN INHIBITOR OF ACTIVATED STAT; PROTEIN KINASE B; PROTEIN SENP1; PROTEIN UBC9; SUMO 1 PROTEIN; SUMO PROTEIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; MESSENGER RNA; SMALL INTERFERING RNA; UBIQUITIN CONJUGATING ENZYME; UBIQUITIN CONJUGATING ENZYME UBC9; UBIQUITIN-CONJUGATING ENZYME UBC9;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; EMBRYO; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE SILENCING; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MODIFICATION; PROTEIN MOTIF; REGULATORY MECHANISM; RNA INTERFERENCE; SUMOYLATION; UBIQUITINATION; WILD TYPE; ADENOCARCINOMA; ANIMAL; ANIMAL EMBRYO; APOPTOSIS; BAGG ALBINO MOUSE; CELL CULTURE; CELL TRANSFORMATION; CYTOLOGY; DRUG ANTAGONISM; ENZYME IMMUNOASSAY; FIBROBLAST; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; IMMUNOPRECIPITATION; LUNG TUMOR; METABOLISM; NONOBESE DIABETIC MOUSE; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCID MOUSE; WESTERN BLOTTING; WOUND HEALING;

ADENOCARCINOMA; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CELLS, CULTURED; EMBRYO, MAMMALIAN; FIBROBLASTS; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED NOD; MICE, NUDE; MICE, SCID; PHOSPHORYLATION; PROTEIN INHIBITORS OF ACTIVATED STAT; PROTO-ONCOGENE PROTEINS C-AKT; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SUMOYLATION; UBIQUITIN-CONJUGATING ENZYMES; UBIQUITINATION; WOUND HEALING;

EID: 84884761456     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-0538     Document Type: Article

References (43)

1. Kerscher O, Felberbaum R, Hochstrasser M. Modification of proteins by ubiquitin and ubiquitin-like proteins. Annu Rev Cell Dev Biol 2006;22:159-80.
2. Kulathu Y, Komander D. Atypical ubiquitylation - the unexplored world of polyubiquitin beyond Lys48 and Lys63 linkages. Nat Rev Mol Cell Biol 2012;13:508-23.
3. Yang XJ, Seto E. Lysine acetylation: codified crosstalk with other posttranslational modifications. Mol Cell 2008;31:449-61.
4. Gareau JR, Lima CD. The SUMOpathway: emerging mechanisms that shape specificity, conjugation and recognition. Nat Rev Mol Cell Biol 2010;11:861-71.
5. Johnson ES. Protein modification by SUMO. Annu Rev Biochem 2004;73:355-82.
6. Martin S, Wilkinson KA, Nishimune A, Henley JM. Emerging extranuclear roles of protein SUMOylation in neuronal function and dysfunction. Nat Rev Neurosci 2007;8:948-59.
7. Kang JS, Saunier EF, Akhurst RJ, Derynck R. The type I TGF-beta receptor is covalently modified and regulated by sumoylation. Nat Cell Biol 2008;10:654-64.
8. Kubota Y, O'Grady P, Saito H, Takekawa M. Oncogenic Ras abrogates MEK SUMOylation that suppresses the ERK pathway and cell transformation. Nat Cell Biol 2011;13:282-91.
9. Woo CH, Shishido T, McClain C, Lim JH, Li JD, Yang J, et al. Extracellular signal-regulated kinase 5 SUMOylation antagonizes shear stress-induced antiinflammatory response and endothelial nitric oxide synthase expression in endothelial cells. Circ Res 2008;102:538-45.
10. Kadare G, Toutant M, Formstecher E, Corvol JC, Carnaud M, Boutterin MC, et al. PIAS1-mediated sumoylation of focal adhesion kinase activates its autophosphorylation. J Biol Chem 2003;278:47434-40.
11. Fernandez-Miranda G, Perez de Castro I, Carmena M, Aguirre-Portoles C, Ruchaud S, Fant X, et al. SUMOylation modulates the function of Aurora-B kinase. J Cell Sci 2010;123:2823-33.
12. Brazil DP, Park J, Hemmings BA. PKB binding proteins. Getting in on the Akt. Cell 2002;111:293-303.
13. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007;129:1261-74.
14. Yang WL, Wu CY, Wu J, Lin HK. Regulation of Akt signaling activation by ubiquitination. Cell Cycle 2010;9:487-97.
15. Yang WL, Wang J, Chan CH, Lee SW, Campos AD, Lamothe B, et al. The E3 ligase TRAF6 regulates Akt ubiquitination and activation. Science 2009;325:1134-8.
16. Chan CH, Li CF, Yang WL, Gao Y, Lee SW, Feng Z, et al. The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis. Cell 2012;149:1098-111.
17. Bae S, Kim SY, Jung JH, Yoon Y, Cha HJ, Lee H, et al. Akt is negatively regulated by the MULAN E3 ligase. Cell Res 2012;22:873-85.
18. Fan CD, Lum MA, Xu C, Black JD, Wang X. Ubiquitin-dependent regulation of phospho-AKT dynamics by the ubiquitin E3 ligase, NEDD4-1, in the insulin-like growth factor-1 response. J Biol Chem 2013;288:1674-84.
19. Solit DB, Basso AD, Olshen AB, Scher HI, Rosen N. Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Res 2003;63:2139-44.
20. Sundaresan NR, Pillai VB, Wolfgeher D, Samant S, Vasudevan P, Parekh V, et al. The deacetylase SIRT1 promotes membrane localization and activation of Akt and PDK1 during tumorigenesis and cardiac hypertrophy. Sci Signal 2011;4:ra46.
21. Liu N, Li H, Li S, Shen M, Xiao N, Chen Y, et al. The Fbw7/human CDC4 tumor suppressor targets proproliferative factor KLF5 for ubiquitination and degradation through multiple phosphodegron motifs. J Biol Chem 2010;285:18858-67.
22. Xiao N, Li H, Luo J, Wang R, Chen H, Chen J, et al. Ubiquitin-specific protease 4 (USP4) targets TRAF2 and TRAF6 for deubiquitination and inhibits TNFalpha-induced cancer cell migration. Biochem J 2012;441: 979-86.
23. Sarge KD, Park-Sarge OK. Detection of proteins sumoylated in vivo and in vitro. Methods Mol Biol 2009;590:265-77.
24. Guillemin I, Becker M, Ociepka K, Friauf E, Nothwang HG. Asubcellular prefractionation protocol for minute amounts of mammalian cell cultures and tissue. Proteomics 2005;5:35-45.
25. Wang R, Wang Y, Liu N, Ren C, Jiang C, Zhang K, et al.FBW7regulates endothelial functions by targeting KLF2 for ubiquitination and degradation. Cell Res 2013;23:803-19.
26. Franke TF, Yang SI, Chan TO, Datta K, Kazlauskas A, Morrison DK, et al. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 1995;81: 727-36.
27. Cubenas-Potts C, Matunis MJ. SUMO: a multifaceted modifier of chromatin structure and function. Dev Cell 2013;24:1-12.
28. Jakobs A, Koehnke J, Himstedt F, Funk M, Korn B, Gaestel M, et al. Ubc9 fusion-directed SUMOylation (UFDS): a method to analyze function of protein SUMOylation. Nat Methods 2007;4:245-50.
29. Maison C, Bailly D, Roche D, Montes de Oca R, Probst AV, Vassias I, et al. SUMOylation promotes de novo targeting of HP1alpha to pericentric heterochromatin. Nat Genet 2011;43:220-7.
30. Kerppola TK. Design and implementation of bimolecular fluorescence complementation (BiFC) assays for the visualization of protein interactions in living cells. Nat Protoc 2006;1:1278-86.
31. Shuai K. Regulation of cytokine signaling pathways by PIAS proteins. Cell Res 2006;16:196-202.
32. Shuai K, Liu B. Regulation of gene-activation pathways by PIAS proteins in the immune system. Nat Rev Immunol 2005;5:593-605.
33. Facchinetti V, Ouyang W, Wei H, Soto N, Lazorchak A, Gould C, et al. The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C. EMBO J 2008;27:1932-43.
34. Datta K, Franke TF, Chan TO, Makris A, Yang SI, Kaplan DR, et al. AH/ PH domain-mediated interaction between Akt molecules and its potential role in Akt regulation. Mol Cell Biol 1995;15:2304-10.
35. Vandermoere F, El Yazidi-Belkoura I, Demont Y, Slomianny C, Antol J, Lemoine J, et al. Proteomics exploration reveals that actin is a signaling target of the kinase Akt. Mol Cell Proteomics 2007;6:114-24.
36. Medema RH, Kops GJ, Bos JL, Burgering BM. AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 2000;404:782-7.
37. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007;448:439-44.
38. Aillet F, Lopitz-Otsoa F, Egana I, Hjerpe R, Fraser P, Hay RT, et al. Heterologous SUMO-2/3-ubiquitin chains optimize IkBa degradation and NF-kB activity. PLoS One 2012;7:e51672.
39. Boormans JL, Korsten H, Ziel-van der Made AC, van Leenders GJ, Verhagen PC, Trapman J. E17K substitution in AKT1 in prostate cancer. Br J Cancer 2010;102:1491-4.
40. Clark VE, Erson-Omay EZ, Serin A, Yin J, Cotney J, Ozduman K, et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO. Science 2013;339:1077-80.
41. Merbl Y, Refour P, Patel H, Springer M, Kirschner MW. Profiling of ubiquitin-like modifications reveals features of mitotic control. Cell 2013;152:1160-72.
42. Gonzalez-Santamaria J, Campagna M, Ortega-Molina A, Marcos-Villar L, de la Cruz-Herrera CF, Gonzalez D, et al. Regulation of the tumor suppressor PTEN by SUMO. Cell Death Dis 2012;3:e393.
43. Huang J, Yan J, Zhang J, Zhu S, Wang Y, Shi T, et al. SUMO1 modification of PTEN regulates tumorigenesis by controlling its association with the plasma membrane. Nat Commun 2012;3:911.